ERBB2 and breast cancer: We studied a panel of seven breast cancer cell lines derived from ER+ (ZR75.1), ER+PR+ (MCF-7 and T47D), HER2+ (HCC-1954), and triple-negative (MDA-MB-231, SUM-149, and SUM-159) breast cancers [24].